Additionally, in our analysis, the GLP-1 RA group had a higher concomitant use of SGLT-2 inhibitors and given the emerging evidence that these medications may have some anti-neoplastic effect, this is a potential confounding factor
Regulatory hurdles: Approval for novel indications (Alzheimers, neurodegenerative diseases) requires very high bar: long follow-ups, clinically meaningful endpoints, safety
This is where body composition comes in, offering insight into clinically significant proportions: body fat and muscle mass
The difference between a safe, effective experience and a risky, disappointing one often comes down to the quality of the product and the expertise of the team administering it
Follow with sunscreen during daytime.